Oxidative Medicine and Cellular Longevity

Review Article

Increased Oxidative Stress as a Selective Anticancer Therapy

Table 1

Surface markers of cancer stem cells in different types of tumors.


Tumor type	CSC markers	References

AML	CD34⁺/CD38⁻, CD44⁺, CD34⁺/CD123⁺, CD47⁺	[6, 100–104]
ALL	CD34⁺/CD10⁻, CD34⁺/CD19⁻	[105]
Bladder cancer	EMA⁻/CD44v6⁺, 67LR⁺/CD66c⁻, CD44⁺/CK⁵⁺/CK20⁻	[106–108]
Breast cancer	Lin⁻/CD44⁺/CD24^−/low/ESA⁺, ALDH1^high, CD55^high, CD44⁺/CD49f^high/CD133/2^high, CD176⁺	[94, 109–112]
Cervical cancer	CD44^high/CD24^low, CD49f⁺/CD133^low	[113, 114]
Colorectal cancer	CD133⁺, CD44⁺/EpCAM⁺, CD44⁺/CD166⁺, CD24⁺/CD29⁺, ALDH1^high, Lgr-5⁺	[97, 115–119]
Esophageal cancer	CD271⁺, CD44⁺/CD24⁻, CD90⁺	[120–122]
Gallbladder carcinoma and cholangiocarcinoma	CD44⁺/CD133⁺, CD24⁺/CD44⁺/EpCAM^high	[123, 124]
Gastric cancer	CD44⁺/CD54⁺, CD90⁺	[125, 126]
Glioma	Podoplanin⁺, CD15⁺, A2B5⁺, CD44⁺, CD133⁺	[127–131]
Head and neck squamous cell carcinomas	CD44⁺, ALDH^high	[95, 132]
Liver cancer	CD90⁺/CD44⁺, CD133⁺/CD44⁺, EpCAM⁺, CD176⁺, CD13⁺,	[90, 112, 133–136]
Lung cancer	CD133⁺, CD44⁺, CD176⁺, CD56⁺, CD90⁺, CD166⁺	[112, 137–140]
Melanoma	ABCB5⁺, CD271⁺, JARID1B⁺, CD133⁺, CD20⁺	[141–145]
Nasopharyngeal cancer	CD44⁺, ALDH1⁺, CD133⁺	[146–148]
Oral squamous carcinoma	CD133⁺, CD44⁺/SSEA-4⁺	[149, 150]
Osteosarcomas	CD44⁺/CD105⁺/Stro1⁺, CD117⁺/Stro-1⁺, Nes⁺/CD133⁺, ABCA5⁺	[151–154]
Ovarian cancer	CD133⁺, CD44⁺, CD117⁺, CD44⁺/CD24⁺, CD105⁺	[155–159]
Pancreatic cancers	CD44⁺/CD24⁺/ESA⁺, CD133⁺, CXCR4⁺	[96, 160]
Prostatic cancer	CD44⁺/Integrinα2β1^high/CD133⁺, Sca-1⁺, PSCA⁺, CD10⁺, CD164⁺	[83, 161–164]
Skin squamous cell carcinoma	CD34⁺, Integrinα5β1^high	[165, 166]

EMA: epithelial membrane antigen; 67LR: 67 kDa laminin receptor; ESA: epithelial special antigen; ALDH1: aldehyde dehydrogenase 1; EpCAM: epithelial cell adhesion molecule; Lgr-5: leucine-rich-repeat containing G-protein-coupled receptor 5; JARID1B: the H3K4 demethylase; Sca-1: stem cell antigen-1; PSCA: prostate stem cell antigen.